Clinical Trial Update: Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC [Phase 2]

View source ↗

Summary

Phase II study of atezolizumab and tiragolumab with ctDNA for HPV-positive oropharyngeal squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: WITHDRAWN